There have been various new developments in blood gas analyzers industry. Leading players are constantly introducing advanced blood gas analyzers with improved features and low cost.
In July 2024, Werfen introduced the new GEM Premium 7000 with Intelligent Quality Management 3 (iQM3) at the ADLM Annual Meeting. The new blood gas analyzer has already received 510(K) clearance from the US Food and Drug Administration.
GEM Premium 7000 represents a breakthrough in blood gas testing. It offers hemolysis detection for the first time at the POC. The latest product is designed to address the growing incidence of frequent preanalytical errors like hemolysis that occur during patient preparation, sampling, or handling of the sample.
GEM Premium 7000 with iQM3 has the tendency to address the problem of hemolysis in point-of-care testing. The company announced that it will strive to expand placement of its new systems throughout the United States and other regions to enhance both patient care and efficiency.
GEM Premium 7000 can deliver a complete snapshot of results (pH, PO2, electrolytes, total hemoglobin, lactate, glucose, SaO2, and other parameters in just 45 seconds. It can allow clinicians to make safe and rapid decisions for the care of patients.
In July 2024, EKF Diagnostics Holding Plc launched its new Biosen C-Line benchtop glucose and lactate analyzer. It is designed to enhance usability through features like touch screen and advanced connectivity. These features enable Biosen C-Line to seamlessly connect with laboratory and hospital IT systems to ensure that patient results are securely and quickly available to clinicians.
In May 2024, Radiometer announced a new commercial partnership with Etiometry to enhance workflows and clinical decision-making in hospital settings. The integration of Etiometry platform with Radiometer’s acute care diagnostic tools will empower clinicians to view blood gas results and other physiologic parameters in clinical care settings.
Recently, EDAN introduced i20, the first-of-its-kind POC blood gas and chemistry analysis system. The new solution is equipped with over 45 parameters, covering electrolyte and blood gasses to CO-oximetry. It is designed to relieve the burden in critical care settings like ICUs, operating rooms, pulmonary units, and neonatal intensive care.
These recent developments showcase the industry’s commitment to innovation, efficiency, and improved patient outcomes. They will play a key role in meeting the demand for efficient blood gas analyzers. Werfen’s GEM Premium 7000 with iQM3 will help to tackle frequent preanalytical errors like hemolysis that occur during patient preparation and sampling.
Introduction of novel POC blood gas devices, like that of EDAN’s, will enable clinicians to obtain rapid and accurate blood gas measurements at the point of care. They will enhance diagnostic efficiency and reduce turnaround time for critical patient assessments.
Integration of AI-driven algorithms and connectivity features in modern blood gas analyzers will streamline data management and clinical decision making. Such innovations are expected to positively impact the global blood gas analyzers industry.
According to Coherent Market Insights (CMI), the global blood gas analyzers industry size is set to reach US$ 4.13 billion by 2032. Overall demand for blood gas analyzers will likely grow at 5.8% CAGR during the assessment period.
Sources:
Companies: Werfen, EDAN, Etiometry
